Literature DB >> 18374761

Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results.

Hiroaki Nomori1, Takeshi Mori, Koei Ikeda, Koichi Kawanaka, Shinya Shiraishi, Kazuhiro Katahira, Yasuyuki Yamashita.   

Abstract

OBJECTIVE: One of the deficiencies of positron emission tomography for N staging in lung cancer is a false-positive result caused by concurrent lymphadenitis. Recently, diffusion-weighted magnetic resonance imaging has been reported to be able to image tumors of body organs. The aim of this study is to examine the usefulness of diffusion-weighted magnetic resonance imaging for N staging of non-small cell lung cancer compared with positron emission tomography-computed tomography.
METHODS: Both positron emission tomography-computed tomography and diffusion-weighted magnetic resonance imaging were prospectively used in 88 patients before surgical intervention for non-small cell lung cancer to examine 734 lymph node stations. The diagnostic results of positron emission tomography-computed tomography and diffusion-weighted magnetic resonance imaging were compared. The diameters of the metastatic foci within lymph nodes were measured on hematoxylin and eosin-stained sections to compare the detectable size of metastatic foci between positron emission tomography-computed tomography and diffusion-weighted magnetic resonance imaging.
RESULTS: The accuracy of N staging in the 88 patients was 0.89 with diffusion-weighted magnetic resonance imaging, which was significantly higher than the value of 0.78 obtained with positron emission tomography-computed tomography (P = .012), because of less overstaging in the former. Among the 734 lymph node stations examined pathologically, 36 had metastases, and the other 698 did not. Although there was no significant difference in the diagnosis of the 36 metastatic lymph node stations between the 2 methods, diffusion-weighted magnetic resonance imaging was more accurate for diagnosing the 698 nonmetastatic stations than positron emission tomography-computed tomography because of fewer false-positive results (P = .002). The detectable size of metastatic foci within lymph nodes was 4 mm in both positron emission tomography-computed tomography and diffusion-weighted magnetic resonance imaging.
CONCLUSIONS: Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography-computed tomography for N staging of non-small cell lung cancer with fewer false-positive results compared with positron emission tomography-computed tomography.

Entities:  

Mesh:

Year:  2008        PMID: 18374761     DOI: 10.1016/j.jtcvs.2007.10.035

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  24 in total

1.  Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.

Authors:  Gregor Sommer; Mark Wiese; Leopold Winter; Claudia Lenz; Markus Klarhöfer; Flavio Forrer; Didier Lardinois; Jens Bremerich
Journal:  Eur Radiol       Date:  2012-07-09       Impact factor: 5.315

2.  N staging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm: initial experience.

Authors:  A A Kohan; J A Kolthammer; J L Vercher-Conejero; C Rubbert; S Partovi; R Jones; K A Herrmann; P Faulhaber
Journal:  Eur Radiol       Date:  2013-06-14       Impact factor: 5.315

3.  Diffusion-weighted imaging can correctly identify false-positive lymph nodes on positron emission tomography in non-small cell lung cancer.

Authors:  Hiroaki Nomori; Yue Cong; Hiroshi Sugimura; Yoshiaki Kato
Journal:  Surg Today       Date:  2015-12-10       Impact factor: 2.549

Review 4.  PET-MRI synergy in molecular, functional and anatomical cancer imaging.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

5.  Comparing diffusion-weighted imaging and positron emission tomography for pulmonary nodules measuring from 1 to 3 cm in size.

Authors:  Hiroaki Nomori; Yue Cong; Hiroshi Sugimura; Yoshiaki Kato
Journal:  Surg Today       Date:  2015-02-13       Impact factor: 2.549

6.  A preliminary exploration of the intravoxel incoherent motion applied in the preoperative evaluation of mediastinal lymph node metastasis of lung cancer.

Authors:  Xin Ye; Shuo Chen; Yaru Tian; Bin You; Wenqian Zhang; Yan Zhao; Tao Jiang; Bin Hu; Hui Li
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

7.  A proposal for combined MRI and PET/CT interpretation criteria for preoperative nodal staging in non-small-cell lung cancer.

Authors:  Yoo Na Kim; Chin A Yi; Kyung Soo Lee; O Jung Kwon; Ho Yun Lee; Byung-Tae Kim; Joon Young Choi; Seon Woo Kim; Man Pyo Chung; Joungho Han; Tae Sung Kim; Myung Jin Chung; Young Mog Shim
Journal:  Eur Radiol       Date:  2012-02-26       Impact factor: 5.315

8.  Discrimination of Malignant versus Benign Mediastinal Lymph Nodes Using Diffusion MRI with an IVIM Model.

Authors:  Li-Ping Qi; Wan-Pu Yan; Ke-Neng Chen; Zheng Zhong; Xiao-Ting Li; Kejia Cai; Ying-Shi Sun; Xiaohong Joe Zhou
Journal:  Eur Radiol       Date:  2017-09-19       Impact factor: 5.315

9.  Benign and malignant enlarged chest nodes staging by diffusion-weighted MRI: an alternative to mediastinoscopy?

Authors:  Monica Sigovan; Pia Akl; Caroline Mesmann; Francois Tronc; Salim Si-Mohamed; Philippe Douek; Loic Boussel
Journal:  Br J Radiol       Date:  2017-12-18       Impact factor: 3.039

10.  Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.

Authors:  Till-Alexander Heusner; Sherko Kuemmel; Angela Koeninger; Monia E Hamami; Steffen Hahn; Anton Quinsten; Andreas Bockisch; Michael Forsting; Thomas Lauenstein; Gerald Antoch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.